Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Quizartinib Plus Induction Chemotherapy Provides Survival Benefit in FLT3 ITD–Mutated AML

September 8th 2023

The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.

Improved Molecular Understanding of AP/BP MPN Better Informs Management Approaches

September 8th 2023

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL

September 8th 2023

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.

Follicular Lymphoma: Patient Monitoring and Maintenance Therapy

September 8th 2023

Before closing out their discussion on first-line management of follicular lymphoma, experts consider the importance of patient monitoring and discuss the diminished role of maintenance therapy.

First-Line Treatment Options for Patients With Follicular Lymphoma

September 8th 2023

Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, review the frontline treatment armamentarium available to patients with follicular lymphoma.

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7th 2023

No difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hematopoietic stem cell transplantation in elderly patients over the age of 60 with acute myeloid leukemia in first complete remission.

Dr Kantarjian on the Predictive Value of Early Responses to Ponatinib in CP-CML

September 7th 2023

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma

September 7th 2023

Jason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Understanding How to Best Measure MRD Negativity in Ph+ ALL

September 7th 2023

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL

September 7th 2023

Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.

Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML

September 7th 2023

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

September 7th 2023

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

September 7th 2023

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL

September 6th 2023

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma

September 6th 2023

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

FDA Approval Sought for Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

September 6th 2023

The FDA has accepted a biologics license application seeking the approval of crovalimab for use in patients with paroxysmal nocturnal hemoglobinuria.

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5th 2023

The National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received at least 1 therapy.

PhALLCON Trial: Safety and Efficacy of Ponatinib in Philadelphia-positive ALL

September 5th 2023

Expert hematologist-oncologists consider how the PhALLCON trial elucidates the safety of ponatinib in Ph+ ALL, highlighting comparable toxicity rates and favorable efficacy endpoints.

Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

September 5th 2023

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

Challenges with Early Diagnosis of GVHD

September 4th 2023

Mahasweta Gooptu, MD shares insights on the early identification and diagnosis of chronic GVHD.